afn-1252 and Osteomyelitis

afn-1252 has been researched along with Osteomyelitis* in 1 studies

Trials

1 trial(s) available for afn-1252 and Osteomyelitis

Article	Year
Bone and Joint Tissue Penetration of the Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:3 Afabicin (formerly Debio 1450, AFN-1720) is a prodrug of afabicin desphosphono (Debio 1452, AFN-1252), a novel antibiotic in development which targets the staphylococcal enoyl-acyl carrier protein reductase (FabI) and exhibits selective potent antibacterial activity against staphylococcal species, including methicillin-resistant Topics: Anti-Bacterial Agents; Arthroplasty, Replacement, Hip; Benzofurans; Bone and Bones; Enoyl-(Acyl-Carrier-Protein) Reductase (NADH); Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Naphthyridines; Osteomyelitis; Prosthesis-Related Infections; Pyrones; Staphylococcal Infections	2019

Article

Year

Bone and Joint Tissue Penetration of the

Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:3

Afabicin (formerly Debio 1450, AFN-1720) is a prodrug of afabicin desphosphono (Debio 1452, AFN-1252), a novel antibiotic in development which targets the staphylococcal enoyl-acyl carrier protein reductase (FabI) and exhibits selective potent antibacterial activity against staphylococcal species, including methicillin-resistant

Topics: Anti-Bacterial Agents; Arthroplasty, Replacement, Hip; Benzofurans; Bone and Bones; Enoyl-(Acyl-Carrier-Protein) Reductase (NADH); Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Naphthyridines; Osteomyelitis; Prosthesis-Related Infections; Pyrones; Staphylococcal Infections

2019